Day: June 15, 2021

TORONTO, June 15, 2021 (GLOBE NEWSWIRE) — Flow Capital Corp. (TSXV: FW) (“Flow Capital”) today announces that it has provided an investment to Performio, an Irvine-based SaaS software Incentive Compensation Management solution. Founded in Melbourne, Australia in 2006, Performio was designed to be flexible and easy to use for mid-market and enterprise companies looking to automate their sales compensation programs. Since its inception, Performio has processed over $2 billion in commissions and has saved its customers over 1 million administrative hours. With Flow Capital’s investment, Performio is aiming to accelerate its growth within the US. “Performio saw over 100% revenue growth in North America in 2020. Flow Capital’s investment will help them invest in sales and marketing more aggressively to further accelerate that sales...

– Collaboration leverages expertise and capabilities of both companies towards developing life-changing treatments for severe neurological diseases – ZUG, Switzerland and CAMBRIDGE, Mass. and THOUSAND OAKS, Calif., June 15, 2021 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, and Capsida Biotherapeutics Inc., a biotechnology company dedicated to developing breakthrough gene therapies using fully integrated adeno-associated virus (AAV) engineering, cargo development and manufacturing, today announced a strategic partnership to research, develop, manufacture and commercialize in vivo gene editing therapies delivered with engineered AAV vectors for the treatment of familial amyotrophic lateral sclerosis (ALS)...

Phase 2 trial will evaluate the efficacy of once-weekly apraglutide in increasing intestinal energy absorption in CIC patients with SBS-IFCIC patients represent over half of the total SBS-IF populationInitial readout of 4-week intestinal energy absorption data expected in 1H22 BASEL, Switzerland, June 15, 2021 (GLOBE NEWSWIRE) — VectivBio Holding AG, (“Vectiv” or “VectivBio”) (Nasdaq: VECT), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions for which there is a significant unmet medical need, today announced it has dosed the first patient in its Phase 2 STARS Nutrition metabolic balance study evaluating apraglutide in colon-in-continuity (CIC) patients with short bowel syndrome with intestinal failure (SBS-IF). CIC patients...

68 shareholders were registered as attending at the Annual General Meeting, who owned 497,278,196 votes/shares (the amount of represented share capital 233,720,725 EUR), forming 74.23% of AS Tallink Grupp share capital. Resolutions adopted at the meeting: 1. To approve the Annual Report of 2020 of AS Tallink Grupp presented by the Management Board. In favour of the resolution voted 100% of the votes represented at the meeting (497,277,169 votes).   2. To approve the proposal presented by the management board of AS Tallink Grupp:1) To approve the net loss of the financial year of 2020 in the amount of 108,308,000 euros and to cover the net loss with the retained earnings;2) No dividend distribution to the shareholders. In favour of the resolution voted 100% of the votes represented at the meeting (497,271,167 votes).   3. To amend the second...

68 shareholders were registered as attending at the Annual General Meeting, who owned 497,278,196 votes/shares (the amount of represented share capital 233,720,725 EUR), forming 74.23% of AS Tallink Grupp share capital. Resolutions adopted at the meeting: 1. To approve the Annual Report of 2020 of AS Tallink Grupp presented by the Management Board. In favour of the resolution voted 100% of the votes represented at the meeting (497,277,169 votes).   2. To approve the proposal presented by the management board of AS Tallink Grupp:1) To approve the net loss of the financial year of 2020 in the amount of 108,308,000 euros and to cover the net loss with the retained earnings;2) No dividend distribution to the shareholders. In favour of the resolution voted 100% of the votes represented at the meeting (497,271,167 votes).   3. To amend the second...

Aleafia Health’s Port Perry Outdoor Cultivation Site86 acre outdoor cultivation facilityTORONTO, June 15, 2021 (GLOBE NEWSWIRE) — Aleafia Health Inc. (TSX: AH, OTCQX: ALEAF) (“Aleafia Health” or the “Company”), a global leader in cannabis wellness products and services, today announced that it has largely completed planting across 86 acres at its outdoor cultivation facility in Port Perry, Ont. The milestone was achieved a month earlier, and on a significantly larger scale, than the 2020 outdoor season, which yielded 31,200 kgs of dried flower, at a cash cost to harvest of $0.10 per gram. “Through the tremendous diligence and hard work of our operations team, we are poised to take another major step forward this year in outdoor cultivation. With all infrastructure completed and licences secured last year,...

– CLS-AX 0.03 mg dose delivered via suprachoroidal injection was well-tolerated with no treatment related adverse events – – Initiating Cohort 2 patient screening for 0.1 mg dose in June 2021 – ALPHARETTA, Ga., June 15, 2021 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today positive safety results from Cohort 1 of OASIS, its ongoing Phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) administered by suprachoroidal injection via Clearside’s SCS Microinjector® in six patients (n=6) with neovascular age-related macular degeneration (wet AMD). The primary endpoints were achieved in Cohort 1, as the initial...

HONKARAKENNE OYJ Stock Exchange Release 15 June 2021 at 14:00 EET CHANGE IN HONKARAKENNE OYJ’S HOLDING OF TREASURY SHARES Honkarakenne Oyj has assigned 10 000 Honkarakenne B-shares as a part of CEO’s performance-based incentive for year 2020. The handover date for the shares was 8 June 2021. After the transfer, Honkarakenne group holds 339 385 of its own class B shares. HONKARAKENNE OYJ Board of Directors Further information: Marko Saarelainen, President and CEO, tel. +358 40 542 0254, marko.saarelainen@honka.com orMaarit Jylhä, Vice President, Finance – CFO, tel. +358 40 594 4099, maarit.jylha@honka.com DISTRIBUTION Nasdaq Helsinki LtdKey mediaFinancial Supervisory Authoritywww.honka.com Honkarakenne supplies high-quality, healthy and ecological log homes, holiday homes and public buildings. Its buildings are made from Finnish solid...